Printer Friendly

UNIMED SHARES TO TRADE ON NASDAQ NATIONAL MARKET EFFECTIVE APRIL 7, 1992

UNIMED SHARES TO TRADE ON NASDAQ NATIONAL MARKET EFFECTIVE APRIL 7, 1992
 SOMERVILLE, N.J., March 20 /PRNewswire/ -- UNIMED, Inc. (NASDAQ: UMED) announced today that its shares will trade on the NASDAQ National Market effective April 7, 1992.
 "Listing on the NASDAQ National Market should facilitate the trading of our stock and improve the visibility of our company in the financial community," said Harold J. Tenoso, Ph.D., Unimed's chairman and chief executive officer.
 Entry into the NASDAQ National Market provides brokers and others with immediate access to the best bid and asked prices and other information about the company's shares throughout the trading day. Those prices are available over more than 190,000 electronic terminals in brokers' offices throughout the United States and the world. Trading data are also distributed through wire services for selective dissemination by newspapers and radio and television stations.
 UNIMED, Inc. specializes in the development and marketing of pharmaceuticals, and emphasis on therapy and supportive care of cancer patients and AIDS patients.
 -0- 3/20/92
 /CONTACT: Charles P. Harrison, president of UNIMED, 908-526-6894/
 (UMED) CO: UNIMED, Inc. ST: New Jersey IN: MTC SU:


TS-OS -- NY007 -- 9996 03/20/92 09:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 20, 1992
Words:198
Previous Article:SOUTHERN NATIONAL COMPLETES ACQUISITION OF WORKMEN'S BANCORP INC.
Next Article:NORTHSTAR COMPUTER FORMS HOLDS ANNUAL MEETING
Topics:


Related Articles
UNIMED REPORTS RECORD SALES OF MARINOL IN FISCAL YEAR RESULTS
UNIMED, LECTEC TO PURSUE TRANSDERMAL DEVELOPMENT OF MARINOL
UNIMED TO REGAIN CANADIAN MARKETING RIGHTS FOR MARINOL
UNIMED REPORTS REVENUE GROWTH OF 46 PERCENT IN FISCAL FIRST QUARTER
UNIMED REPORTS PROCEEDS OF $9.26 MILLION FROM WARRANT EXERCISE
UNIMED REPORTS SECOND QUARTER RESULTS
UNIMED INTRODUCES MARINOL IN AUSTRALIA AND PUERTO RICO
UNIMED PHARMACEUTICALS CLOSES $8.4 MILLION PRIVATE PLACEMENT; CHAIRMAN EXERCISES WARRANTS
UNIMED PHARMACEUTICALS ANNOUNCES COLLABORATION WITH BIOCHEM FOR CANADA
Unimed Pharmaceuticals Announces Stock Repurchase Program

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters